Drug-induced pneumonitis associated with imatinib mesylate in a patient with idiopathic pulmonary fibrosis

Respiration

Volumn 75, Issue 3, 2008, Pages 350-354

  Yamasawa, Hideaki ^a   Sugiyama, Yukihiko ^a   Bando, Masashi ^a   Ohno, Shoji ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

Drug induced pneumonitis; Idiopathic pulmonary fibrosis; Imatinib mesylate

Indexed keywords

HYDROXYUREA; IMATINIB; METHYLPREDNISOLONE; PREDNISOLONE;

AGED; ARTICLE; CASE REPORT; CHRONIC MYELOID LEUKEMIA; COMPUTER ASSISTED TOMOGRAPHY; COUGHING; DISEASE COURSE; DRUG MEGADOSE; DRUG WITHDRAWAL; DYSPNEA; FACE EDEMA; FIBROSING ALVEOLITIS; HISTOPATHOLOGY; HUMAN; LABORATORY TEST; MALE; MUSCLE CRAMP; PHYSICAL EXAMINATION; PNEUMONIA; PRIORITY JOURNAL; THORAX RADIOGRAPHY; TRANSBRONCHIAL BIOPSY;

AGED; ANTINEOPLASTIC AGENTS; COMORBIDITY; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LUNG; LUNG DISEASES, INTERSTITIAL; MALE; PIPERAZINES; PULMONARY FIBROSIS; PYRIMIDINES; TOMOGRAPHY, X-RAY COMPUTED;

EID: 41349098797     PISSN: 00257931     EISSN: None     Source Type: Journal    
DOI: 10.1159/000091272     Document Type: Article

References (16)

1. Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C, Niederwieser D, Resta D, Capdeville R, Zoellner U, Talpaz M, Druker B, Goldman J, O'Brien SG, Russell N, Fischer T, Ottmann O, Cony-Makhoul P, Facon T, Stone R, Miller C, Tallman M, Brown R, Schuster M, Loughran T, Gratwohl A, Mandelli F, Saglio G, Lazzarino M, Russo D, Baccarani M, Morra E;International STI571 CML Study Group: Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002;346:645-652.
2. American Thoracic Society: Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. Am J Respir Crit Care Med 2000;161:646-664.
3. Bergeron A, Bergot E, Vilela G, Ades L, Devergie A, Esperou H, Socie G, Calvo F, Gluckman E, Ribaud P, Rousselot P, Tazi A: Hypersensitivity pneumonitis related to imatinib mesylate. J Clin Oncol 2002;20:4271-4272.
4. Rosado MF, Donna E, Ahn YS: Challenging problems in advanced malignancy: case 3. Imatinib mesylate-induced interstitial pneumonitis. J Clin Oncol 2003;21:3171-3173.
5. Ma CX, Hobday TJ, Jett JR: Imatinib mesylate-induced interstitial pneumonitis. Mayo Clin Proc 2003;78:1578-1579.
6. Yokoyama T, Miyazawa K, Kurakawa E, Nagate A, Shimamoto T, Iwaya K, Akata S, Aoshima M, Serizawa H, Ohyashiki K: Interstitial pneumonia induced by imatinib mesylate: pathologic study demonstrates alveolar destruction and fibrosis with eosinophilic infiltration. Leukemia 2004;18:645-646.
7. Isshiki I, Yamaguchi K, Okamoto S: Interstitial pneumonitis during imatinib therapy. Br J Haematol 2004;125:420.
8. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, Fletcher JA, Silverman SG, Silberman SL, Capdeville R, Kiese B, Peng B, Dimitrijevic S, Druker BJ, Corless C, Fletcher CD, Joensuu H: Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347:472-480.
9. Apperley JF, Gardembas M, Melo JV, Russell-Jones R, Bain BJ, Baxter EJ, Chase A, Chessells JM, Colombat M, Dearden CE, Dimitrijevic S, Mahon FX, Marin D, Nikolova Z, Olavarria E, Silberman S, Schultheis B, Cross NC, Goldman JM: Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med 2002;347:481-487.
10. Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J, Kutok J, Clark J, Galinsky I, Griffin JD, Cross NC, Tefferi A, Malone J, Alam R, Schrier SL, Schmid J, Rose M, Vandenberghe P, Verhoef G, Boogaerts M, Wlodarska I, Kantarjian H, Marynen P, Coutre SE, Stone R, Gilliland DG: A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003;348:1201-1214.
11. Nagaoka I, Trapnell BC, Crystal RG: Upregulation of platelet-derived growth factor-A and -B gene expression in alveolar macrophages of individuals with idiopathic pulmonary fibrosis. J Clin Invest 1990;85:2023-2027.
12. Homma S, Nagaoka I, Abe H, Takahashi K, Seyama K, Nukiwa T, Kira S: Localization of platelet-derived growth factor and insulin-like growth factor I in the fibrotic lung. Am J Respir Crit Care Med 1995;152:2084-2089.
13. Zhang P, Gao WY, Turner S, Ducatman BS: Gleevec (STI-571) inhibits lung cancer cell growth (A549) and potentiates the cisplatin effect in vitro. Mol Cancer 2003;2:1.
14. Ranson M, Hammond LA, Ferry D, Kris M, Tullo A, Murray PI, Miller V, Averbuch S, Ochs J, Morris C, Feyereislova A, Swaisland H, Rowinsky EK: ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. J Clin Oncol 2002;20:2240-2250.
15. Inoue A, Saijo Y, Maemondo M, Gomi K, Tokue Y, Kimura Y, Ebina M, Kikuchi T, Moriya T, Nukiwa T: Severe acute interstitial pneumonia and gefitinib. Lancet 2003;361:137-139.
16. Suzuki H, Aoshiba K, Yokohori N, Nagai A: Epidermal growth factor receptor tyrosine kinase inhibition augments a murine model of pulmonary fibrosis. Cancer Res 2003;63:5054-5059.